Unknown

Dataset Information

0

Balancing Trained Immunity with Persistent Immune Activation and the Risk of Simian Immunodeficiency Virus Infection in Infant Macaques Vaccinated with Attenuated Mycobacterium tuberculosis or Mycobacterium bovis BCG Vaccine.


ABSTRACT: Our goal is to develop a pediatric combination vaccine to protect the vulnerable infant population against human immunodeficiency virus type 1 (HIV-1) and tuberculosis (TB) infections. The vaccine consists of an auxotroph Mycobacterium tuberculosis strain that coexpresses HIV antigens. Utilizing an infant rhesus macaque model, we have previously shown that this attenuated M. tuberculosis (AMtb)-simian immunodeficiency virus (SIV) vaccine is immunogenic, and although the vaccine did not prevent oral SIV infection, a subset of vaccinated animals was able to partially control virus replication. However, unexpectedly, vaccinated infants required fewer SIV exposures to become infected compared to naive controls. Considering that the current TB vaccine, Mycobacterium bovis bacillus Calmette-Guérin (BCG), can induce potent innate immune responses and confer pathogen-unspecific trained immunity, we hypothesized that an imbalance between enhanced myeloid cell function and immune activation might have influenced the outcome of oral SIV challenge in AMtb-SIV-vaccinated infants. To address this question, we used archived samples from unchallenged animals from our previous AMtb-SIV vaccine studies and vaccinated additional infant macaques with BCG or AMtb only. Our results show that vaccinated infants, regardless of vaccine strain or regimen, had enhanced myeloid cell responses. However, CD4+ T cells were concurrently activated, and the persistence of these activated target cells in oral and/or gastrointestinal tissues may have facilitated oral SIV infection. Immune activation was more pronounced in BCG-vaccinated infant macaques than in AMtb-vaccinated infant macaques, indicating a role for vaccine attenuation. These findings underline the importance of understanding the interplay of vaccine-induced immunity and immune activation and its effect on HIV acquisition risk and outcome in infants.

SUBMITTER: Jensen K 

PROVIDER: S-EPMC5216431 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Balancing Trained Immunity with Persistent Immune Activation and the Risk of Simian Immunodeficiency Virus Infection in Infant Macaques Vaccinated with Attenuated Mycobacterium tuberculosis or Mycobacterium bovis BCG Vaccine.

Jensen Kara K   Dela Pena-Ponce Myra Grace MG   Piatak Michael M   Shoemaker Rebecca R   Oswald Kelli K   Jacobs William R WR   Fennelly Glenn G   Lucero Carissa C   Mollan Katie R KR   Hudgens Michael G MG   Amedee Angela A   Kozlowski Pamela A PA   Estes Jacob D JD   Lifson Jeffrey D JD   Van Rompay Koen K A KK   Larsen Michelle M   De Paris Kristina K  

Clinical and vaccine immunology : CVI 20170105 1


Our goal is to develop a pediatric combination vaccine to protect the vulnerable infant population against human immunodeficiency virus type 1 (HIV-1) and tuberculosis (TB) infections. The vaccine consists of an auxotroph Mycobacterium tuberculosis strain that coexpresses HIV antigens. Utilizing an infant rhesus macaque model, we have previously shown that this attenuated M. tuberculosis (AMtb)-simian immunodeficiency virus (SIV) vaccine is immunogenic, and although the vaccine did not prevent o  ...[more]

Similar Datasets

| S-EPMC7457186 | biostudies-literature
| S-EPMC3910917 | biostudies-literature
| S-EPMC8007627 | biostudies-literature
| S-EPMC4344265 | biostudies-literature
| S-EPMC5501492 | biostudies-literature
| S-EPMC143318 | biostudies-literature
| S-EPMC4360911 | biostudies-literature
| S-EPMC2885305 | biostudies-literature
| S-EPMC135468 | biostudies-literature
| S-EPMC4972778 | biostudies-literature